Translational Development Acquisition Corp. (TDACW) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 42.00 means the share price is 42.00 times one year of earnings per share.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerTranslational Development Acquisition Corp. (TDACW) trades at $1.40. Translational Development Acquisition Corp. is a special purpose acquisition company (SPAC) focused on identifying and merging with a private business. Sector: Financials.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for TDACW: TDACW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
Translational Development Acquisition Corp. (TDACW) Financial Services Profile
Translational Development Acquisition Corp. is a blank check company aiming to acquire a private entity through a merger, share exchange, or similar transaction. Incorporated in 2022, the company operates within the financial conglomerates sector, seeking opportunities to create value through business combinations, but currently has no operations.
What Is the Investment Thesis for TDACW?
Translational Development Acquisition Corp. presents a speculative investment opportunity tied to its ability to identify and successfully merge with a target company. The company's value is currently derived from its cash holdings and the potential upside of a future acquisition. Key value drivers include the management team's experience in deal-making and the attractiveness of the target company. A successful merger could lead to significant stock appreciation, while failure to find a suitable target within the specified timeframe could result in liquidation and return of capital to shareholders. The company's beta of -0.01 suggests a low correlation with the overall market, but this is likely to change upon announcement of a merger target.
Based on FMP financials and quantitative analysis
TDACW Key Highlights
Incorporated in 2022, indicating a relatively new entity in the SPAC market.
- Operates with only 2 employees, reflecting its pre-acquisition operational structure.
- Intends to pursue a merger, share exchange, or similar business combination, highlighting its focus on acquiring a target company.
- Currently has no significant operations, emphasizing its status as a blank check company.
- Based in New York City, providing access to a large network of potential target companies and investors.
Who Are TDACW's Competitors?
TDACW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| APXT Apex Technology Acquisition Corp. | $10.15 | 0.00% | $1.89B | 76 5-pillar |
| DMII Drugs Made In America Acquisition II Corp. | $10.19 | 0.00% | $649M | 55 5-pillar |
| BCSS Bain Capital GSS Investment Cor | $10.28 | -0.10% | $482M | 53 5-pillar |
| CEPF Cantor Equity Partners IV, Inc. | $10.27 | 0.00% | $471M | 52 5-pillar |
| TACO Berto Acquisition Corp. | $10.46 | -0.10% | $392M | 53 5-pillar |
| ALUB ALUB | $10.13 | -0.10% | $364M | 45 5-pillar |
| TACH Titan Acquisition Corp. | $10.54 | 0.00% | $364M | 47 5-pillar |
| CCII Cohen Circle Acquisition Corp. II | $10.31 | +0.10% | $358M | 49 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TDACW's Key Strengths?
Access to capital through IPO.
- Flexibility to pursue a wide range of target companies.
- Potential for high returns if a successful merger is completed.
What Are TDACW's Weaknesses?
No current operations or revenue.
- Dependence on identifying and acquiring a suitable target company.
- Competition from other SPACs and private equity firms.
What Are the Key Risks for TDACW?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Rich valuation — a P/E of 42.00 runs well above the Financial Services sector’s ~17.20x, leaving little room for a miss.
- Failure to identify a suitable target company within the specified timeframe, leading to liquidation and return of capital to shareholders.
- Unsuccessful merger due to regulatory hurdles, market conditions, or shareholder opposition.
- Competition from other SPACs and private equity firms seeking similar acquisition opportunities.
What Are TDACW's Competitive Advantages?
- Management team's experience in deal-making and industry expertise.
- Access to capital raised through the IPO.
- Network of contacts and relationships to identify potential target companies.
What Does TDACW Do?
Translational Development Acquisition Corp. was founded in 2022 and is based in New York City. The company functions as a special purpose acquisition company, or SPAC. Its primary objective is to identify and merge with a private company, thereby taking the target company public without the traditional IPO process. TDACW has no current operations. The company intends to pursue a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. SPACs like Translational Development Acquisition Corp. offer private companies an alternative route to accessing public markets, while providing investors an opportunity to invest in a potentially high-growth company before it becomes publicly traded. The success of Translational Development Acquisition Corp. hinges on its ability to identify and merge with a promising target company. The company's small size, with only 2 employees, reflects its current pre-acquisition status.
What Products and Services Does TDACW Offer?
- Acts as a special purpose acquisition company (SPAC).
- Seeks to identify a private company for a potential merger.
- Aims to take a private company public through acquisition.
- Raises capital through an initial public offering (IPO).
- Evaluates potential target companies for business combination opportunities.
- Negotiates and executes merger agreements with target companies.
- Provides a route for private companies to access public markets.
How Does TDACW Make Money?
- Raise capital through an IPO to form a SPAC.
- Identify and merge with a private company.
- Generate returns for investors through stock appreciation following a successful merger.
What Industry Does TDACW Operate In?
Translational Development Acquisition Corp. operates within the SPAC market, a segment of the financial industry characterized by companies formed to raise capital through an initial public offering (IPO) for the purpose of acquiring an existing company. The SPAC market has experienced periods of rapid growth and increased scrutiny. The success of SPACs depends on the ability of their management teams to identify attractive acquisition targets and complete mergers that create value for shareholders. The competitive landscape includes numerous other SPACs seeking similar opportunities, as well as traditional private equity firms and strategic acquirers.
Who Are TDACW's Key Customers?
- Investors seeking exposure to private companies through public markets.
- Private companies looking for an alternative to the traditional IPO process.
- Shareholders who invest in the SPAC prior to the merger.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is a warrant, not an operating company
Financial Health
Translational Development Acquisition Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 22.98 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on equity for Translational Development Acquisition Corp. stands at 3.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.5%, showing how much profit it generates from its asset base. TDACW trades at a trailing price-to-earnings ratio of 42.00, above the Financial Services sector average of ~17.20x. Its free cash flow yield is -0.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 3.0%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Translational Development Acquisition Corp. operates in the Financial Services sector. It is headquartered in New York City, US. The company is led by CEO Michael Hoffman. TDACW has traded publicly since 2025.
TDACW Financials
Bull Case vs Bear Case
Bull Case
- Access to capital through IPO.
- Flexibility to pursue a wide range of target companies.
- Potential for high returns if a successful merger is completed.
- Upcoming: Announcement of a potential merger target, which could drive significant investor interest and stock appreciation.
Bear Case
- No current operations or revenue.
- Dependence on identifying and acquiring a suitable target company.
- Competition from other SPACs and private equity firms.
- Potential: Failure to identify a suitable target company within the specified timeframe, leading to liquidation and return of capital to shareholders.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TDACW Latest News
No recent news available for TDACW.
TDACW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for TDACW.
Price Targets
Wall Street price target analysis for TDACW.
TDACW MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for TDACW; grades run from A+ (80-100) to F (below 30).
Leadership: Michael Hoffman
Unknown
Without additional context, it is difficult to provide a comprehensive overview of his career history, education, or previous roles. His experience and expertise are critical to the success of Translational Development Acquisition Corp.
Track Record: Information about Michael Hoffman's track record is not available in the provided data. Without specific details on his previous achievements, strategic decisions, or company milestones under his leadership, it is challenging to assess his past performance and its potential impact on Translational Development Acquisition Corp.
What Investors Ask About Translational Development Acquisition Corp. (TDACW) — Financials
What does Translational Development Acquisition Corp. do?
Translational Development Acquisition Corp. functions as a special purpose acquisition company (SPAC). It is a blank check company formed to raise capital through an initial public offering (IPO) with the intention of acquiring a private company.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on limited data available.
- The company's future performance is highly dependent on its ability to identify and acquire a suitable target company.